In Brief Objective: We began a controlled clinical trial to assess efficacy and toxicity of surgery (S), + radiotherapy (SRT), chemotherapy (SCT), (CT) in the treatment primary gastric diffuse large cell lymphoma early stages: IE II1. Summary Background Data: Management remains controversial. No trials have evaluated different therapeutic schedules, prognostic factors not been identified uniform population. Patients Methods: Five hundred eighty-nine patients were randomized be treated with S...

<i>Objectives:</i> To assess the efficacy and toxicity of most employed therapeutic approaches in treatment primary breast lymphoma (PBL). <i>Methods:</i> Ninety-six patients with PBL early stage (I or II) were enrolled to receive radiotherapy (45 Gy); chemotherapy (six cycles cyclophosphamide, doxorubicin, vincristine prednisone (CHOP), every 21 days), combined therapy. <i>Results:</i> Complete response was achieved 20 30 treated radiotherapy, 19 32 who...

Angiocentric T cell/natural killer (NK) nasal lymphoma remains a rare clinical presentation in North America and Europe but is more common Asia Latin America. We have reviewed 108 cases of angiocentric T/NK cell the cavity with view to establishing prognostic factors. Most patients were high or intermediate risk had additional poor factors such as bulky disease, levels beta 2 microglobulin, advanced stage multiple extranodal involvement. At 8 years, overall survival was 82%, 90% 84% for...

Abstract Treatment of hematological malignancies (HM) during pregnancy remain unsolved, although the use chemotherapy second and third trimester has been accepted because low rate toxicities, cytotoxic drugs first is generally forbidden. Most concerns are related to congenital abnormalities development, but long‐term follow‐up these children not available. From 1975 2008, we diagnosed treated 15,750 cases HM, 143 female patients were pregnant this time that with combined chemotherapy. In our...

Primary lung lymphoma (PLL) and diffuse large B‐cell (DLBCL) is a rare entity the biological features, clinical presentation, prognosis markers treatment have not been well defined. We present 82 cases of PLL‐DLBCL in uniform population treated with conventional chemotherapy: CHOP (cyclophosphamide, doxorubicin vincristine prednisone). To best our knowledge, this largest series long term follow reported. also performed immunohistochemical studies to determine if cell origin [germinal center...

Anthracyclines are a group of drugs that useful in the treatment Hodgkin's disease, but have been associated with severe, and some cases lethal, cardiac toxicity. Apparently, toxicity is more frequent after 10 years anthracycline therapy, no longer studies reported. Four hundred seventy-six patients stages III IV, were randomly assigned to receive ABVD (doxorubicin, bleomycin, vinblastine dacarbazine) compared EBVD (epirubicin instead doxorubicin) MBVD (mitoxantrone at standard doses. The...

To analyze the role of genotype in patients with diffuse large B-cell lymphoma primary breast (DLBCL-PB) treated chemotherapy or immunochemotherapy.We carried out a retrospective analysis 104 DLBCL-PB who were CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) immunochemotherapy: R-CHOP (adding rituximab) also an genotype, studied immunohistochemistry, as prognostic factor.Seventy-seven percent showed non-GCB (germinal center B) genotype. Patients had complete response 70%;...

Treatment of refractory mycosis fungoides and Sézary syndrome remain unsatisfactory. In this study, we assessed the efficacy toxicity low-dose methotrexate (10 mg/m2, biweekly) interferon (9.0 MU, three times a week) as induction therapy by 6 or 12 months, followed, if patients achieved complete remission, maintenance until relapse. an intent-to-treat analysis, 158 were considered evaluable. Complete response (biopsy proven) was observed in 112 (49 [31%] at months 63 [49%] months); thus,...

ObjectivesTreatment of refractory/relapsed cutaneous T-cell lymphoma (CTCL) remains controversial, most studies included a few patients with short follow-up. Previously, we performed two small employing interferon alpha 2b (IFN) combined low doses methotrexate (MTX) or retinoids. Thus, conducted an open-label clinical trial to assess the benefit and toxicity mentioned regimens in large number longer follow-up treatment CTCL.Patients methodsThree-hundred seventy-seven refractory/relapsed,...

Krüppel-Like Factor 4 (KLF4) is a member of the KLF transcription factor family, and evidence suggests that KLF4 either an oncogene or tumor suppressor. The regulatory mechanism underlying expression in cancer, specifically lymphoma, still not understood. Bioinformatics analysis revealed two YY1 putative binding sites promoter region (-950 bp -105 bp). Here, potential regulation by NHL was analyzed. Mutation previously reported system containing CHIP confirmed these are important for...

We performed a retrospective analysis to assess the influence of different prognostic factors, including International Prognostic Index (IPI), that can predict outcome in patients with primary large bowel lymphoma (Stage IE) treated combined therapy (surgery followed by chemotherapy).All were radical surgery six cycles chemotherapy: CHOP-Bleo (cyclophosphamide, doxorubicine, vincristine, prednisone, and bleomycin) or variants (epirubicin instead doxorubicin). In all cases, an multivariate...

RETRACTED

Purpose: We perfomed a phase II clinical trial to assess the efficacy and toxicity of addition rituximab conventional chemotherapy in primary gastric lymphoma (PGL). Methods: Forty-two (42) patients with PGL, stage IE IIE, low- or low-intermediate risk were treated prospective longitudinal study standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) (375 mg/m2, intravenously) on day 1 each cycle administered every 21 days, for 6 cycles. The endpoint was improvement outcome...

A growing body of evidence is demonstrating that the nitrogen-containing bisphosphonate zoledronic acid (zol) improves clinical outcomes in various cancer settings, including multiple myeloma. Those findings provided rationale for conducting an open-label randomized controlled phase iii trial to evaluate effect zol on overall survival (os) and progression-free (pfs) patients with previously untreated high-risk myeloma.The randomly assigned 308 adult less than 65 years age symptomatic myeloma...

The discovery and description of the role microRNAs has become very important, specifically due to their participation in regulation proteins transcription factors involved development cancer. microRNA-7 (miR-7) been described as a negative regulator several cancer, such YY1 KLF4. We have recently reported that KLF4 play non-Hodgkin lymphoma (NHL) expression is regulated by YY1. Therefore, this study we analyzed miR-7 NHL through qRT-PCR showed there an inverse relation B-NHL cell lines....